Haemonetics 2026 Q1 Earnings Net Income Falls 11.3%

Haemonetics reported its fiscal 2026 Q1 earnings on August 8, 2025. The earnings reflect a challenging quarter with both revenue and net income falling year-over-year, despite continued investment in key product innovation and international expansion. The results fell short of market expectations in several key metrics. The company provided no updated guidance for the full fiscal year.

Haemonetics reported total revenue of $321.39 million for the first quarter of fiscal 2026, a 4.4% decline compared to $336.17 million in the same period last year. Plasma segment revenue stood at $129.90 million, while the Blood Center segment generated $51.84 million. The Hospital segment contributed $139.66 million to the total net revenues. These figures reflect ongoing pressures from supply chain disruptions and pricing challenges in key markets.

The company’s earnings per share (EPS) fell to $0.71 in 2026 Q1, representing a 5.3% drop from $0.75 in 2025 Q1. Net income also declined to $34.03 million, a 11.3% fall from $38.37 million the previous year. The drop in profitability highlights the impact of rising operational costs and lower-than-expected revenue performance across several segments.

The stock price of Haemonetics experienced significant declines following the earnings release, with a 22.82% drop during the latest trading day and a 26.77% month-to-date plunge. The performance suggests investor concern over the company’s short-term outlook and the broader market’s cautious response to the earnings report.

A strategy of buying Haemonetics shares after the revenue decline and holding for 30 days showed only moderate returns. The strategy returned an annualized growth rate (CAGR) of 2.83%, significantly below the market benchmark, which saw a 41.51% outperformance. The maximum drawdown of 0.00% and a Sharpe ratio of 0.09 indicate minimal risk exposure but also limited upside potential, underscoring the stock’s lackluster performance post-earnings.

CEO Patrick T. Mahaffy highlighted the continued adoption of the NexSys PCS® plasma collection system and expansion of the VASCADE® portfolio as key growth drivers. However, he noted ongoing challenges including supply chain constraints and reimbursement pressures in certain markets. Strategic priorities include accelerating innovation in blood and plasma management technologies and deepening digital integration through recent acquisitions such as OpSens and Attune Medical. Mahaffy expressed cautious optimism for the remainder of the year, emphasizing the importance of market diversification and operational efficiency in driving long-term value creation.

Haemonetics expects full-year revenue growth to be supported by increased plasma collection yield and international expansion. The company remains focused on product innovation and operational excellence. While no specific revenue or EPS guidance was provided for the year, the CEO reaffirmed confidence in maintaining double-digit growth in key product segments, supported by recent regulatory approvals and a robust product pipeline.

Additional News
On the same day as Haemonetics' earnings report, several key developments in Nigeria included President Bola Tinubu's approval of measures to address pension backlogs and enhance public welfare, as well as the Red Cross launching a second phase of a food intervention program in Lagos. Additionally, the West African Examinations Council (WAEC) released revised 2025 WASSCE results following grading errors. In business news, Stanbic IBTC announced a savings promotion where 148 customers won a total of N23 million. Meanwhile, political factions within the African Democratic Congress denounced internal leadership claims, and Nigerian startups gained attention for their growing focus on software innovation.